Latest Darbepoetin alfa Stories
EXTON, Pa., April 27 /PRNewswire/ -- BioTrends Research Group, Inc.
EXTON, Pa., Dec. 1 /PRNewswire/ -- BioTrends Research Group, Inc. released its third TreatmentTrends(TM): European Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and Canadian Nephrology.
Blood transfusions used to treat anemia in patients with cancer are associated with an increased risk of life-threatening blood clots, U.S. researchers say.
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients.
Affymax, a biopharmaceutical company, has announced positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients.
Medgenics (AIM:MEDG), is pleased to announce encouraging preliminary data for its Phase I/II clinical trial. The landmark Phase I/II clinical trial of Medgenics' EPODURE Biopump, for providing sustained treatment of anemia in subjects with chronic kidney disease, is underway.
The U.S. Food and Drug Administration issued an advisory about preliminary results of a German study involving the drug known as Procrit, Eprex or Epogen.
Amgen (NASDAQ:AMGN) today announced that it has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products L.P. (Ortho Biotech).
Affymax has completed enrollment in the first of four Phase III clinical trials of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients.
- To play, gamble.
- To impose upon; delude; trick; humbug; also, to joke; chaff.
- A deceitful game or trick; trickery; humbug; nonsense.